SPINK 1 Protein Expression and Prostate Cancer Progression
View/ Open
Author
Flavin, Richard
Pettersson, Andreas
Hendrickson, Whitney
Fiorentino, Michelangelo
Finn, Stephen
Kunz, Lauren
Judson, Gregory
Lis, Rosina
Bailey, Dyane
Fiore, Christopher
Nuttall, Elizabeth
Martin, Neil
Stack, Edward
Penney, Kathryn
Rider, Jennifer
Sinnott, Jennifer
Sweeney, Christopher
Sesso, Howard
Fall, Katja
Giovannucci, Edward
Kantoff, Philip
Loda, Massimo
Mucci, Lorelei
Published Version
https://doi.org/10.1158/1078-0432.CCR-13-1341Metadata
Show full item recordCitation
Flavin, R., A. Pettersson, W. K. Hendrickson, M. Fiorentino, S. Finn, L. Kunz, G. L. Judson, et al. 2014. “SPINK1 Protein Expression and Prostate Cancer Progression.” Clinical Cancer Research 20 (18): 4904–11. https://doi.org/10.1158/1078-0432.ccr-13-1341.Abstract
Purpose: SPINK1 overexpression has been described in prostate cancer and is linked with poor prognosis in many cancers. The objective of this study was to characterize the association between SPINK1 overexpression and prostate cancer-specific survival.Experimental Design: The study included 879 participants in the U. S. Physicians' Health Study and Health Professionals Follow-Up Study, diagnosed with prostate cancer (1983-2004) and treated by radical prostatectomy. Protein tumor expression of SPINK1 was evaluated by immunohistochemistry on tumor tissue microarrays. Results: Seventy-four of 879 (8%) prostate cancer tumors were SPINK1 positive. Immunohistochemical data were available for PTEN, p-Akt, pS6, stathmin, androgen receptor (AR), and ERG (as a measure of the TMPRSS2: ERG translocation). Compared with SPINK1-negative tumors, SPINK1-positive tumors showed higher PTEN and stathmin expression, and lower expression of AR (P < 0.01). SPINK1 overexpression was seen in 47 of 427 (11%) ERG-negative samples and in 19 of 427 (4%) ERG-positive cases (P = 0.0003). We found no significant associations between SPINK1 status and Gleason grade or tumor stage. There was no association between SPINK1 expression and biochemical recurrence (P = 0.56). Moreover, there was no association between SPINK1 expression and prostate cancer mortality (there were 75 lethal cases of prostate cancer during a mean of 13.5 years follow-up; HR = 0.71; 95% confidence interval, 0.29-1.76). Conclusions: Our results suggest that SPINK1 protein expression may not be a predictor of recurrence or lethal prostate cancer amongst men treated by radical prostatectomy. SPINK1 and ERG protein expression do not seem to be entirely mutually exclusive, as some previous studies have suggested.Terms of Use
This article is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAPCitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41292538
Collections
- SPH Scholarly Articles [6354]
Contact administrator regarding this item (to report mistakes or request changes)